Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
More research is needed on the safety and efficacy of multiple biologics.
Combining biologics for patients with inflammatory bowel disease (IBD) could be beneficial for patients that do not respond to initial biologic treatment.
And as new biologics continue to be developed and tested, it has become important to learn how multiple biologics can react together and whether or not this could effectively treat IBD.
In an interview with HCPLive®, Amar Deshpande, MD, Department of Medical Education, University of Miami Miller School of Medicine, discussed how studying the safety and efficacy of biologics could be important in treating IBD.
Deshpande recently spoke about this topic during the Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease event chaired by Maria T. Abreu, MD, University of Miami Miller School of Medicine on August 31.
He said it is more common to combine biologics with a non-biologic. But adding 2 biologics can be an answer based on the data from several studies for patients with more complicated disease or a worse prognosis.
Another option outside of giving patients 2 biologics at once is sequentially using biologics.
However, Deshpande said this research is still early and more studies on the possibilities of biologics for IBD are needed.
And as the field advances, researching how biologics can interact is going to essential.